The World Health Organization reports 30,000 suspected mpox cases in Africa this year, with over 800 deaths, mostly in the Democratic Republic of Congo. The World Bank is allocating $128.89 million to support ten African countries in battling the outbreak.
The World Health Organization stated that approximately 30,000 suspected mpox cases have been documented in Africa this year, with a majority occurring in the Democratic Republic of Congo where testing supplies have been depleted.
The U.N. health body reported that over 800 people passed away from suspected mpox across the continent during that period. Additionally, Burundi, a neighbouring country in central Africa to Congo, has also been impacted by an increasing outbreak.
The public health agency of the African Union has reported a total of 14,957 cases and 739 deaths in seven affected states in 2023, showing a 78.5% rise in new cases compared to 2022. According to the WHO report, Africa recorded 29,342 suspected cases and 812 deaths between January and Sept. 15 this year.
The WHO stated that in August alone, there were 2,082 confirmed cases reported globally, marking the highest number since November 2022.
The World Bank's pandemic fund announced on Saturday that it will provide $128.89 million to ten African countries to support efforts against the outbreak.
Read next
19:00
Pope Francis
Vatican City, February 20, 2025 – Pope Francis will not appear in public on Sunday to lead his customary prayer with pilgrims, marking the second consecutive week of absence, the Vatican announced on Saturday.
19:21
WHO
The World Health Organization (WHO) has confirmed that the risk to the general population from H5N1 bird flu remains low, despite the first reported death from the virus in the United States.
13:53
Local hospitals are overrun by a mysterious illness. The Sudanese town of al-Hilalya has seen at least 73 deaths according to local doctors. It comes as violence and displacement in eastern El Gezira state continue to intensify. It has been under siege by the paramilitary Rapid Support Forces (RSF).
22:46
AstraZeneca’s new weight-loss pill, AZD5004, shows promise in early trials with tolerable side effects, advancing to Phase II studies focused on reducing obesity.
13:36
An analysis of U.S. health claims reveals that while GLP-1 drugs like Wegovy may aid weight loss, they significantly increase medical costs—rising to $18,507 annually—without reducing obesity-related health events, raising concerns for insurers and employers.
What is your opinion on this topic?
Leave the first comment